A Randomized Placebo-Controlled Trial of Citalopram for Anxiety Disorders Following Traumatic Brain Injury
Abstract
The overarching goal of this project was to study the effects of a serotonin reuptake inhibitor (SRI), citalopram, for the treatment of anxiety experienced by individuals after traumatic brain injury (TBI). Specifically, this project sought to treat individuals who meet criteria for DSM-IV diagnosis of Anxiety Disorder Due to a General Medical Condition, within 3 to 24 months of TBI. A randomized placebo controlled design with 1-year follow-up was utilize to evaluate the effectiveness of citalopram in alleviating significant anxiety symptoms that cause significant distress and can lead to medical retirement active duty soldiers. 19 participants (8 Citalopram and 11 placebo) completed the study. The study did not find significant differences in the anxiety measures between the Citalopram and placebo groups at the week 12 assessment. However, the Citalopram group had lower scores [STAI and HAM-A] than the placebo group. The lack of statistical significance may have been due in part to the small sample size. The small sample size resulted from difficulties identifying service members who were able to participate in this study as a result of war injuries from OIF/OEF.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2009
- Accession Number
- ADA504714
Entities
People
- Michael S. Jaffee
Organizations
- Henry M. Jackson Foundation for the Advancement of Military Medicine